Tetragon Partners GP
Tetragon Partners GP reported 33 stocks worth $758M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PATH (55.1%), KGEI (5.6%) and SLN (3.5%). Compared with Q2 2026, the fund opened new positions in NBIX, AXSM and UBER, added to PATH, SLN and PHVS, trimmed WK, RLAY and ANNX and sold out of AMLX, ACAD and CUE.
Latest filing: what Tetragon Partners GP did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PATH Uipath Inc | $417M | 55.1% | 32.5M | +1.6M (+5%) | 8 of 8 | |
| 2 | ![]() KGEI Kolibri Global Energy Inc | $42.3M | 5.6% | 6.8M | No change | 8 of 8 | |
| 3 | ![]() SLN Silence Therapeutics PLC | $26.6M | 3.5% | 2.4M | +1.7M (+219%) | 4 of 8 | |
| 4 | ![]() PHVS Pharvaris N V | $26.6M | 3.5% | 838K | +543K (+184%) | 7 of 8 | |
| 5 | ![]() IONS Ionis Pharmaceuticals Inc | $19.7M | 2.6% | 441K | +344K (+354%) | 3 of 8 | |
| 6 | ![]() AUTL Autolus Therapeutics PLC | $18.4M | 2.4% | 9.5M | No change | 8 of 8 | |
| 7 | ![]() ARWR Arrowhead Pharmaceuticals in | $17.3M | 2.3% | 264K | +134K (+102%) | 5 of 8 | |
| 8 | ![]() LYFT Lyft Inc | $15M | 2.0% | 1M | No change | 8 of 8 | |
| 9 | ![]() WK Workiva Inc | $15M | 2.0% | 225K | −25K (−10%) | 6 of 8 | |
| 10 | ![]() MBX Mbx Biosciences Inc | $12.9M | 1.7% | 221K | +17K (+8%) | 5 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Tetragon Partners GP 13F FAQ
What does Tetragon Partners GP own?
Tetragon Partners GP reported 33 stocks worth $758M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PATH (55.1%), KGEI (5.6%) and SLN (3.5%). The table above lists every position in the filing (the top 10 without an account).
What did Tetragon Partners GP buy and sell in Q3 2026?
Compared with Q2 2026: 5 new positions, 16 added to, 5 trimmed and 4 sold out. New positions include NBIX, AXSM and UBER. It sold all of AMLX, ACAD and CUE.
When will Tetragon Partners GP file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Tetragon Partners GP's portfolio worth?
The Q3 2026 filing reports $758M in US stocks ($766M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























